4 results
Primary• To assess the effects of RVT-101 versus placebo on global function as measured by the Clinician*s Interview-Based Impression of Change Plus Caregiver Input (CIBIC+) after 24 weeks of treatment• To assess the effects of RVT-101 versus…
To assess the long-term safety and tolerability of 35 mg and 70 mg RVT-101 in subjects with DLB
Primary objectives- A multicenter, open label non-randomized phase I/II dose escalation study with extension cohort to determine the safety, tolerability and immunogenicity of the therapeutic LRPAP1 synthetic long peptide ( LRPAP7-30V-SLP) vaccine (…
Main study: primary vaccination regimenPrimary Objective: 1. To determine the difference in the antibody response against SARS-CoV-2 in PLWH 4 weeks after the completed vaccination schedule with one of the two available mRNA vaccines (BNT162b2 or…